Physician profile
John Peters
NPI 1013004860
$867.41
in general payments reported to CMS, 2019-2025
14 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.24 · 2021: $40.16 · 2023: $380 · 2024: $167 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $205.63 | 2021-2025 | Tremfya |
| Amgen INC. | $148.03 | 2024-2025 | Otezla, Otezla |
| Abbvie INC. | $144.98 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $61.59 | 2023-2025 | |
| Galderma Laboratories, L.P. | $59.66 | 2024-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $45.57 | 2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $35.34 | 2024-2025 | |
| Genzyme Corporation | $35.11 | 2023 | |
| Incyte Corporation | $31.48 | 2023-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $26.59 | 2023 | Libtayo |
| Mayne Pharma Commercial LLC | $26.59 | 2023 | |
| Ucb, INC. | $20.25 | 2025 | Bimzelx |
| Fresenius Kabi USA, LLC | $14.35 | 2023 | Idacio |
| Pfizer INC. | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.